Development of a novel diagnostic method for bladder cancer

2015 Fiscal Year Final Research Report

• Project/Area Number: 25462471
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: Kanagawa Cancer Center Research Institute (2015); The University of Tokyo (2013)
• Principal Investigator: Koshikawa Naohiko 地方独立行政法人神奈川県立病院機構神奈川県立がんセンター(臨床研究所), その他部局等, 部長 (70334282)
• Co-Investigator(Renkei-kenkyūsha): SHUIN Taro 高知大学, 副学長 (70128601) ; KAMADA Masayuki 高知大学, 医学部泌尿器科学教室, 非常勤講師 (90304683) ; KARASHIMA Takashi 高知大学, 医学部泌尿器科学教室, 講師 (60304672)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: バイオマーカー / 診断 / 治療奏効 / 膀胱がん

Outline of Final Research Achievements

In this study we analyzed serum monomeric lamininγ2 (Ln-γ2) as a biomarker for urological cancers. First, we established a quantitative sandwich ELISA using a specific antibody to monomeric Ln-γ2, and was able to measure 50 pg/mL of monomeric Ln-γ2 in serum specimens. After screening using serum specimens obtained from patient with urological cancers, the high levels of monomeric Ln-γ2 was observed in serum of bladder and renal cancers.
Furthermore, to assess whether a specific antibody to monomeric Ln-γ2 as a DDS tool for bladder cancer therapy, we established an intravesical model with bladder cancer cells expressing monomeric Ln-γ2 in nude mice. Now the specific antibody is immunohistochemically assessing in the mouse model with HT-1197 cell expressing high level of endogenous monomeric Ln-γ2.

Free Research Field

腫瘍生化学